Diacomit and Fluoxetine Delayed-Release Capsules
Determining the interaction of Diacomit and Fluoxetine Delayed-Release Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:FLUoxetine may increase the blood levels of stiripentol in some patients. This may increase the risk and/or severity of side effects such as loss of appetite, nausea, vomiting, weight loss, drowsiness, dizziness, confusion, difficulty concentrating, impaired muscle coordination, muscle weakness, tremor, speech problems, and low white blood cell and platelet counts (which can increase the risk of infection and bleeding). Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 1A2, 2C19, and/or 3A4 may increase the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.
MANAGEMENT: Caution is advised when stiripentol is used with CYP450 1A2, 2C19, and/or 3A4 inhibitors. Patients should be monitored for potentially increased adverse effects such as anorexia, nausea, vomiting, weight loss, somnolence, dizziness, confusion, difficulty concentrating, ataxia, hypotonia, tremor, hyperkinesia, dysarthria, suicidal ideation/behaviour, neutropenia, and thrombocytopenia. Dosage adjustments for stiripentol or alternative treatments may be required if an interaction is suspected.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- "Product Information. Diacomit (stiripentol)." Biocodex Inc, Creswell, OR.
Generic Name: fluoxetine
Brand name: Prozac, Prozac Weekly, PROzac Pulvules, Sarafem, Rapiflux, Selfemra
Synonyms: Fluoxetine, FLUoxetine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Diacomit-Fluoxetine Hydrochloride
- Diacomit-Fluoxetine Solution
- Diacomit-Fluoxiv Cream
- Diacomit-Fluoxymesterone
- Diacomit-Fluphenazine
- Diacomit-Fluphenazine decanoate
- Fluoxetine Delayed-Release Capsules-Dialyvite
- Fluoxetine Delayed-Release Capsules-Dialyvite 3000
- Fluoxetine Delayed-Release Capsules-Dialyvite 5000
- Fluoxetine Delayed-Release Capsules-Dialyvite 800/Iron
- Fluoxetine Delayed-Release Capsules-Dialyvite Supreme D
- Fluoxetine Delayed-Release Capsules-Dialyvite Vitamin D 5000